Astellas Wins OSI But Victory Comes At A Price

Japanese drugmaker Astellas Pharma's painstaking pursuit of OSI Pharmaceuticals is officially over. The victory came at a price, however, costing $4 billion, about $500 million more than Astellas' original hostile bid, launched in late February. That Astellas and OSI managed to find a path forward isn't surprising. Both companies had too much at stake not to see the merger come to fruition.

Japanese drugmaker Astellas Pharma Inc.'s painstaking pursuit of OSI Pharmaceuticals LLC is officially over. On May 17, 2010 came news that the two companies had agreed to a definitive merger agreement, enjoying the unanimous support of both companies' boards. The victory came at a price, however, costing $4 billion, about $500 million more than Astellas' original hostile bid, launched in late February. [See Deal] As of June 8, more than 53 million shares—approximately 93% of OSI's issued and outstanding shares--had been validly tendered, allowing Astellas to proceed with the acquisition via Delaware's short-form merger process, which doesn't require approval from OSI shareholders.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By 

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By 

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.